Rituximab (RTX), a monoclonal antibody targeting the CD20+ B lymphocytes, deserves major attention as therapeutic option in the treatment of demyelinating disorders of the central nervous system (DDCNS). We reported our clinical experience with the use of RTX in terms of efficacy and safety in persons suffering from DDCNS.

Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience

D'Amico, Emanuele
Conceptualization
;
Zanghì, Aurora
Methodology
;
Chisari, Clara Grazia;Fermo, Salvatore Lo;ARENA, SEBASTIANO;Patti, Francesco;Zappia, Mario
2019-01-01

Abstract

Rituximab (RTX), a monoclonal antibody targeting the CD20+ B lymphocytes, deserves major attention as therapeutic option in the treatment of demyelinating disorders of the central nervous system (DDCNS). We reported our clinical experience with the use of RTX in terms of efficacy and safety in persons suffering from DDCNS.
2019
Demyelinating disease; Efficacy; Multiple sclerosis; Rituximab; Safety
File in questo prodotto:
File Dimensione Formato  
Mult. Scler. Rel. Disord. 2019.pdf

solo gestori archivio

Tipologia: Versione Editoriale (PDF)
Dimensione 1.95 MB
Formato Adobe PDF
1.95 MB Adobe PDF   Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11769/360472
Citazioni
  • ???jsp.display-item.citation.pmc??? 20
  • Scopus 40
  • ???jsp.display-item.citation.isi??? 39
social impact